Examining physicians’ behaviors regarding buprenorphine prescribing for opioid use disorder
Journal of Opioid Management · 2026
DOI: 10.5055/jom.0978 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Opioid Management, 2026. Verfasst von Khashayar Eshtiaghi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Chapman University School of Pharmacy, Irvine, California. ORCID: https://orcid.org/0000-0003-3678-2166. Hauptthemen laut MEDLINE: Buprenorphine, Opioid-Related Disorders, Practice Patterns, Physicians', Narcotic Antagonists. Die Arbeit nennt 47 Literaturangaben.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Background
The opioid overdose crisis affects approximately 2.1 million Americans with opioid use disorder (OUD). Buprenorphine is an effective treatment that reduces mortality and supports recovery, yet physician perceptions and behaviors influence its prescribing. Understanding these factors is crucial for expanding access. This study examines California physicians’ prescribing behaviors regarding buprenorphine for OUD.
Methods
A cross-sectional survey was conducted via Qualtrics among California physicians. In total, we received 101 completed responses, representing various specialties and practice environments. Descriptive and inferential statistical methods, including independent t-tests, Wilcoxon signed-rank tests, and Kruskal–Wallis tests, were used to analyze the data and examine demographic differences in prescribing behaviors.
Results
Most respondents indicated a low demand for buprenorphine treatment and disagreed with the adequacy of naloxone access in overdose situations. Many of the physicians did not view Drug Enforcement Administration (DEA) interference as a major concern and felt that stigma did not hinder their ability to treat OUD. Male physicians reported obtaining buprenorphine training to be more challenging than did their female counterparts. Physicians in suburban settings expressed greater concerns about DEA involvement than those in urban areas. Furthermore, physicians with a Drug Addiction Treatment Act-Waiver felt better supported and trained than those without one.
Conclusion
This study sheds light on California physicians’ views and behaviors regarding prescribing buprenorphine for OUD. The challenges related to required training for buprenorphine prescribing indicate an area that needs further research. Additionally, concerns about DEA regulations in suburban areas and limited access to naloxone in overdose situations highlight the need for targeted interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Chapman University School of Pharmacy, Irvine, California. ORCID: https://orcid.org/0000-0003-3678-2166.
- Chapman University School of Pharmacy, Irvine, California.
- Chapman University School of Pharmacy, Irvine, California. ORCID: https://orcid.org/0000-0003-0575-7988.
Zitieren
APA
Eshtiaghi, K., Bhatjire, P., Shirazi, A. S., & Fleming, M. (2026). Examining physicians’ behaviors regarding buprenorphine prescribing for opioid use disorder. Journal of Opioid Management. https://doi.org/10.5055/jom.0978
Vancouver
Eshtiaghi K, Bhatjire P, Shirazi AS, Fleming M. Examining physicians’ behaviors regarding buprenorphine prescribing for opioid use disorder. Journal of Opioid Management. 2026. doi:10.5055/jom.0978
BibTeX
@article{Eshtiaghi2026,
author = {Eshtiaghi, Khashayar and Bhatjire, Poonam and Shirazi, Aryan Shokrollah and Fleming, Marc},
title = {Examining physicians’ behaviors regarding buprenorphine prescribing for opioid use disorder},
journal = {Journal of Opioid Management},
year = {2026},
doi = {10.5055/jom.0978}
}
EUVIMED